Study the signal transduction pathway of your choice
Li Xu Chao-Feng Zheng
Stratagene Cloning Systems, Inc.
The PathDetect in vivo signal transduction pathway reporting systems are designed for assessing the in vivo activation of signal transduction pathways. The PathDetect trans-reporting systems include a unique fusion trans-activator plasmid that expresses pathway-specific trans-activator proteins fused to the yeast GAL4 DNA binding domain. To facilitate the construction and expression of new fusion trans-activator proteins, Stratagene has designed the new pFA-CMV plasmid for expressing the activation domain of any transcription factor fused to the yeast GAL4 DNA binding domain. The pFA-CMV plasmid features a multiple cloning site and the cytomegalovirus (CMV) promoter for convenient construction and high-level expression of fusion trans-activator proteins in a variety of mammalian cell lines. We describe two new fusion trans-activator plasmids (constructed with the pFA-CMV plasmid) expressing GAL4 fusions with c-Fos (208-313) and ATF2 (1-96).
Recently, Stratagene introduced the PathDetect in
vivo signal transduction pathway trans-reporting systems, which
are designed for specific, rapid and convenient assessment of the in vivo
activation of signal transduction pathways.1 These reporting
systems are used for studying the in vivo effects of new genes, growth
factors, drug candidates and extracellular stimuli on the activation of
c-Jun N-terminal kinase (JNK),2,3 mitogen-activated protein
kinase (MAPK),4,5 cyclic AMP-dependent protein (PKA)6
and other signaling molecules leading to the activation of these kinases.
The PathDetect report